semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thoracic Cancer Abdominal Cancer Patients must be willing and capable to provide informed consent to participate in the protocol. 2. Patient with presumed pulmonary function capable of holding breath for at least 30 seconds later to be confirmed. 3. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and until study imaging is complete. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 3.1 A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 3.2 Patients must be compliant to all required pretreatment evaluations  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus 2. Patients are not compliant to all required pretreatment evaluations
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HPV-associated Cancer Study participants who received one booster dose of Gardasil 9 at month 24 and elected not to receive the second booster at month 30 in the original "HPV vaccine delayed booster trial" Ability to understand and the willingness to sign a written informed consent document by the legal representative(s) of the participant Ability to understand and the willingness to sign a written assent document by the participant  Has received any HPV vaccine dose from an external source at any point during or after participation in the HPV vaccine delayed booster trial
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 50.0-65.0,  Obesity obesity (BMI 30-40 kg/m2) age 50-65 menopause sedentary women and non-smoking women who did not drink more than six glasses (one glass: 125 mL) of wine a week and did not drink hard liquor (alcohol content at least 20% alcohol by volume) women who agreed not to take part in any other weight loss program  evidence of heart, kidney or liver disease women who met the Diagnostic and Statistical Manual-IV (DSM-V) for a current diagnosis of major depressive disorder taking any medications for weight loss control of cholesterol and triglycerides for anti-inflammatory purposes pregnancy lactating Type 1 diabetes mellitus, irritable bowel disease, celiac disease, chronic pancreatitis antibiotic use in the last three months probiotic/prebiotic treatment in the last four weeks
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 45.0-65.0,  Menopause Surgical Macula Edema Visual Acuity Reduced Transiently Newly diagnosed menopause (Natural or Surgical Menopause( At least 3 months after surgery) No history of illness(Diabetes,Heart disease,Kidney disease etc.) Not Smoking Did not use alcohol Have not use any medication Age between 45-65 years BMI between 20-25 kg/m  Smoking or Alchohol consumption Age before 45 and after 65 years Have chronic disease Using any medication Have not diagnosed Menopause BMI greater than 30 kg/m
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Dysplasia, Cervix Patients over 18 years referred for conization of cervix due to cervical dysplasia  patients under 18 years pregnant women
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Skin Lesion Mucosal Lesion All ages Patients with a muco-cutaneous lesion(s) amenable to imaging by non-invasive tools Healthy volunteer subjects Ability to give informed consent or in the case of pediatric patients, assent and consent from the parent/guardian  Allergy or intolerance to ultrasound gel or mineral oil used for imaging Patients who are not able to comply with imaging procedure
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 20.0-40.0,  Infertility Primary (1) Age between 20 and 40 years old. (2) Cases with history of total fertilization failure in previous ICSI cycles (3) Oocytes with normal morphology  (1) Abnormal oocyte morphology degenerated or immature oocytes. (2) Husbands with spermatogenic arrest or Sertoli/Leydig cells only
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Dysplasia Histologically confirmed High Grade Squamous Intraepithelial Lesion (HSIL) Colposcopically visible lesion No therapy of the disease so far  Pregnancy of the patient at/after in the study; pregnancy after conization and before the control after 6 months is possible and does not lead to from the study Taking immunosuppressive drugs (incl. glucocorticoids) Known HIV positivity Malignant disease requiring treatment Unsatisfactory colposcopy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Anxiety Pregnant women between 20 weeks gestation with a diagnosis of opiate use disorder receiving care through Banner University Medical Center North Mothers Over Medicine (MOMs) Clinic, a high-risk pregnancy clinic for women with substance use disorder complicating pregnancy  Inability to speak or understand English 2. Incarcerated individuals 3. Age <18 yo
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Intraepithelial Neoplasia Squamous Intraepithelial Lesions of the Cervix Uterine Cervical Dysplasia Reproductive age and aspirations of future pregnancies Acceptance of conservative management Commitment to attend scheduled follow-up visits Colposcopy with transformation zone (ZT) type 1 or 2 (fully visible squamous-columnar union) with lesion with grade 2 changes visible in its entirety. No endocervical involvement Colposcopy with grade 2 changes that are not extensive: <50% of the cervical surface  Pregnancy at first visit or during follow-up Immunosuppression (either iatrogenic or due to human immunodeficiency virus (HIV)) Suspected or diagnosed Atypical Glandular Cells (ACG), In Situ Adenocarcinoma (AIS) or Cervical Cancer (CC)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-54.0,  HPV Infection Willing to disclose HIV status HIV negative women aged 30-54 years; HIV positive women aged 25-54 years Mentally competent to give informed consent Physically able to have a pelvic exam  Women reporting no previous sexual activity History of cervical cancer Treatment for cervical precancer in the last six months Hysterectomy Pregnancy Serious pre-existing medical conditions (e.g. history of bleeding disorders, serious physical or mental disease)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Adenocarcinoma of Breast Histology-confirmed epithelial cancer of the mammary gland Pre and post menopausal patients with early breast cancer and involved axillary lymph nodes (T 1-3 N1 M0) or high-risk N0 patients. A N0 patient is considered "high-risk" if she fulfills at least one of the following criteria; T>= 2cm, Estrogen Receptor (ER)/Progesterone receptor (PgR) negative, HER-2 3+, infiltration of blood or lymphatic vessels or nerves, grade 3 White Blood Cell count (WBC) > 4 x 109 / l, platelets > 100 x 109 / l Serum creatinine, Aspartate aminotransferase (AST/SGOT),Alanine aminotransferase (ALT/SGPT), gamma-glutamyltransferase, serum bilirubin 1.3 mg/ml inside the normal range of the participating hospital Performance status (WHO) 0 or 1 Age >=18 years Previous surgical treatment: Either radical surgery or, for a partial mastectomy, a histologically confirmed safe margin of 2 cm or more and the results of the axillary node dissection available No evidence of significant cardiac disease  History of myocardial infarction within the previous 12 months or heart failure (including cardiac insufficiency controlled by digitalis and diuretics) or arrhythmias requiring medication or uncontrolled arterial hypertension (BP> 200/110 mm Hg). A normal baseline Left Ventricular Ejection Fraction (LVEF) should be demonstrated by multigated acquisition (MUGA) scan or echocardiogram No previous antitumor chemotherapy or radiation Time from surgery 2 to 4 weeks
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Pediatric Tumor Clinical cases who are suspected for and provisionally diagnosed for "neck swelling" in children (below age of 18 years)  Patients with conditions that may hinder ultrasound examination like subcutaneous emphysema and thick skin scarring. 2. Patients who are unwilling/uncooperative or have not given consent for participation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diamond Blackfan Anemia Dyskeratosis Congenita Fanconi Anemia Shwachman Diamond Syndrome Inherited Bone Marrow Failure Syndrome, Aplastic Anemia Fanconi s anemia Diamond Blackfan anemia Dyskeratosis congenita Shwachman Diamond Syndrome Amegakaryocytic thrombocytopenia Thrombocytopenia absent radii Severe congenital neutropenia Pearson s Syndrome Other bone marrow failure syndromes First degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or full), biologic parents, and children  Evidence that the hematologic disorder is acquired rather than genetic. Such evidence includes temporal relation of the aplastic anemia to known marrow suppressant drugs, chemicals, toxins, or viruses (in the absence of evidence indicative of an inherited marrow failure disorder) Known causes of cytopenias such as autoantibodies to red cells, platelets, or neutrophils, viruses (especially hepatitis), micronutrient deficiencies, transient erythroblastopenia of childhood, and cyclic neutropenia Assignment of the patient s physical findings to other syndromes or causes that are not part of the IBMFS disease spectrum Unwillingness to permit access to medical records and pathology specimens. There are no other parameters not related to the primary disease
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Chronic Active Epstein-Barr Virus CAEBV Study size: up to 150 patients Sex distribution: male and female Age range: 1 year old and above Patients with known or suspected CAEBV and their relatives will be recruited by referrals from health care providers. The rarity of this disease will markedly limit the number of patients available to study; therefore, we will enroll patients who are 1 year of age and older. However, children under the age of 3 years old will be enrolled as samples only participants and not be evaluated at the Clinical Center. Patient recruitment is irrespective of racial and ethnic group or gender. NIAID investigators will be available to answer questions and discuss general aspects of CAEBV and identified genes or modifier genes with participants or their providers. To be considered having CAEBV, a patient must have: 1. a severe progressive illness that began as a primary EBV infection, or associated with postive EBV-specific antibody titers (IgG-VCA, ; EA or EBNA) not otherwise explained AND 2. evidence of major organ involvement such as lymphadenitis, hemophagocytosis, meningoencephalitis, persistent hepatitis, splenomegaly, interstitial pneumonitis, bone marrow hypoplasia, uveitis AND 3. detection of elevated levels of EBV DNA, RNA or proteins in affected tissues OR elevated levels of EBV DNA in the peripheral blood  (a) Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in the study. OF CAEBV Study size: up to 150 relatives of CAEBV patients Age range: 3 years and above To determine the genetic basis for this syndrome, the evaluation of blood, saliva and/or previously obtained tissue specimens from healthy relatives of CAEBV patients will serve as controls. No tissue biopsies will be performed on healthy relatives. We will perform some of the studies listed on samples from normal relatives. Study size: up to 300 persons Age range: 18 years and above Panels of anonymous blood samples will be obtained through NIH Clinical Center Blood Transfusion Medicine to determine if identified genetic changes are mutations or polymorphisms
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Anemia Fatigue Prostate Cancer Histologically confirmed prostate cancer Hormone-refractory disease as evidenced by progression on bone scan or CT scan with a rising prostate-specific antigen Prior bilateral orchiectomy OR other primary hormonal therapy (e.g., estrogen therapy or luteinizing hormone-releasing hormone analog [LHRH] and flutamide) with evidence of treatment failure Concurrent continual LHRH agonist therapy (e.g., depot leuprolide or goserelin) required for patients who have not undergone bilateral orchiectomy Must have anemia with hemoglobin ≥ 8 g/dL and < 12 g/dL within the past 14 days Must be iron replete (i.e., ferritin > 50 ng/mL) within the past 30 days Presence of fatigue with usual fatigue severity ≥ 3 on the 0-10 numerical scale of the Brief Fatigue Inventory within the past 14 days Age and over Performance status ECOG 0-3 Life expectancy Not specified Hematopoietic
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 15.0-19.0,  Infections, Meningococcal Healthy male or female between, and including, 15 and 19 years of age at the time of vaccination Subject with previously completed routine childhood vaccinations to the best of his/her knowledge or his/her parents'/guardians' knowledge Female subjects should be of non-childbearing potential  Previous vaccination against OR history of OR exposure within previous 12 months to meningococcal serogroup A, C, W-135 or Y disease Administration of a tetanus vaccine within 6 months before study vaccination Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection A family history of congenital or hereditary immunodeficiency History of any neurologic disorders or seizures
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Kidney Failure, Acute Intensive Care patients with sepsis Patients with acute kidney failure: serum creatinin > 2 mg/dl Chronic haemodialysis patients  < 18 years
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.083-18.0,  Kawasaki Disease Patients who fulfill the of Kawasaki disease or atypical Kawasaki disease and their household family members  Not cases of Kawasaki disease